


# PROCESS SCALE PURIFICATION OF ANTIBODIES



EDITED BY  
Uwe Gottschalk

 WILEY

# CONTENTS

<b>Preface</b>	<b>xvii</b>
<b>About the Author</b>	<b>xxi</b>
<b>Contributors</b>	<b>xxiii</b>
<b>1 Downstream Processing of Monoclonal Antibodies: Current Practices and Future Opportunities</b>	<b>1</b>
<i>Brian Kelley, Greg Blank, and Ann Lee</i>	
1.1 Introduction, 1	
1.2 A Brief History of cGMP mAb and Intravenous Immunoglobulin (IgIV) Purification, 2	
1.3 Current Approaches in Purification Process Development: Impact of Platform Processes, 4	
1.4 Typical Unit Operations and Processing Alternatives, 8	
1.5 VLS Processes: Ton-Scale Production and Beyond, 11	
1.6 Process Validation, 13	
1.7 Product Life Cycle Management, 15	
1.8 Future Opportunities, 17	
1.9 Conclusions, 20	
1.10 Acknowledgments, 21	
1.11 References, 21	

<b>2</b>	<b>The Development of Antibody Purification Technologies</b>	<b>25</b>
	<i>John Curling</i>	
2.1	Introduction, 25	
2.2	Chromatographic Purification of Antibodies before Protein A, 27	
2.3	Antibody Purification after 1975, 31	
2.4	Additional Technologies for Antibody Purification, 32	
2.5	Purification of mAbS Approved in North America and in Europe, 37	
2.6	Acknowledgments, 44	
2.7	References, 45	
<b>3</b>	<b>Harvest and Recovery of Monoclonal Antibodies: Cell Removal and Clarification</b>	<b>53</b>
	<i>Abhinav A. Shukla and Jagannadha Rao Kandula</i>	
3.1	Introduction, 53	
3.2	Centrifugation, 56	
3.3	Microfiltration, 58	
3.4	Depth Filtration, 64	
3.5	Flocculation, 68	
3.6	Absolute Filtration, 70	
3.7	Expanded-Bed Chromatography, 72	
3.8	Comparison of Harvest and Clarification Unit Operations, 73	
3.9	Acknowledgments, 74	
3.10	References, 75	
<b>4</b>	<b>Protein A-Based Affinity Chromatography</b>	<b>79</b>
	<i>Suresh Vunnum, Ganesh Vedantham, and Brian Hubbard</i>	
4.1	Introduction, 79	
4.2	Properties of Protein A and Commercially Available Protein A Resins, 80	
4.2.1	Protein A Structure, 80	
4.2.2	Protein A–Immunoglobulin G (IgG) Interaction, 80	
4.2.3	Stoichiometry of Protein A–IgG Binding, 81	
4.2.4	Protein A Stability, 81	
4.2.5	Commercial Protein A Resins, 81	
4.2.6	Static Capacity, 83	
4.2.7	DBC, 83	
4.2.8	Leaching, 84	
4.2.9	Production Rates, 85	
4.3	Protein A Chromatography Step Development, 85	
4.3.1	Loading/Binding, 86	
4.3.2	Wash Development, 87	

4.3.3	Elution, 88	
4.3.4	Stripping, 89	
4.3.5	Regeneration and CIP, 89	
4.4	Additional Considerations During Development and Scale-Up, 90	
4.4.1	Controlling HMW Formation, 91	
4.4.2	Removal of Soluble HMW Contaminants, 91	
4.4.3	Turbidity, 92	
4.5	Virus Removal/Inactivation, 94	
4.5.1	Virus Removal, 95	
4.5.2	Low-pH Inactivation, 95	
4.5.3	Bovine/Transmissible Spongiform Encephalopathy (BSE/TSE) Clearance, 96	
4.6	Validation and Robustness, 96	
4.6.1	Validation, 96	
4.6.2	Robustness, 97	
4.7	Conclusions, 97	
4.8	Acknowledgments, 98	
4.9	References, 99	
<b>5</b>	<b>Purification of Human Monoclonal Antibodies: Non-Protein A Strategies</b>	<b>103</b>
	<i>Alahari Arunakumari and Jue Wang</i>	
5.1	Introduction, 103	
5.2	Integrated Process Designs for Human Monoclonal Antibody (HuMab) Production, 105	
5.3	Purification Process Designs for HuMabs, 106	
5.3.1	Protein A Purification Schemes, 106	
5.3.2	Non-Protein A Purification Schemes, 107	
5.3.3	Host Cell Protein (HCP) Exclusion Approach for Ion-Exchange Purification Schemes, 108	
5.4	Conclusions, 119	
5.5	Acknowledgments, 121	
5.6	References, 121	
<b>6</b>	<b>Purification of Monoclonal Antibodies by Mixed-Mode Chromatography</b>	<b>125</b>
	<i>Pete Gagnon</i>	
6.1	Introduction, 125	
6.2	A Brief History, 126	
6.3	Prerequisites for Industrial Implementation, 127	
6.4	Mechanisms, Screening, and Method Development, 129	
6.5	Capture Applications, 137	

- 6.6 Polishing Applications, 138
- 6.7 Sequential Capture/Polishing Applications, 139
- 6.8 The Future, 139
- 6.9 Acknowledgments, 140
- 6.10 References, 140

## **7 Integrated Polishing Steps for Monoclonal Antibody Purification 145**

*Sanchayita Ghose, Mi Jin, Jia Liu, and John Hickey*

- 7.1 Introduction, 145
- 7.2 Polishing Steps in Antibody Purification, 146
  - 7.2.1 Ion-Exchange (IEX) Chromatography, 146
  - 7.2.2 HIC, 151
  - 7.2.3 HA Chromatography, 155
  - 7.2.4 Mixed-Mode and Other Modes of Chromatography, 156
  - 7.2.5 Dedicated Virus Removal Steps, 158
- 7.3 Integration of Polishing Steps, 159
  - 7.3.1 Case Study I: Selection and Placement of Polishing Steps, 159
  - 7.3.2 Case Study II: Selection of Operational Mode and Influence of the Previous Polishing Step, 161
- 7.4 Conclusions, 163
- 7.5 Acknowledgments, 163
- 7.6 References, 164

## **8 Orthogonal Virus Clearance Applications in Monoclonal Antibody Production 169**

*Joe X. Zhou*

- 8.1 Introduction, 169
- 8.2 Model Viruses and Virus Assays, 170
- 8.3 Virus Clearance Strategies from First in Human (FIH) to Biological License Application (BLA) Filing, 172
- 8.4 Orthogonal Viral Clearance in mAb Production, 173
  - 8.4.1 Major Viral Clearance Steps: Capture, Low-pH Viral Inactivation, and Polishing, 173
  - 8.4.2 Disposable Systems, 173
- 8.5 Conclusions and Future Perspectives, 183
- 8.6 Acknowledgments, 184
- 8.7 References, 184

## **9 Development of A Platform Process for the Purification of Therapeutic Monoclonal Antibodies** **187**

*Yuling Li, David W. Kahn, Olga Galperina, Erich Blatter, Robert Luo, Yaling Wu, and Guihang Zhang*

- 9.1 Introduction, 187
- 9.2 Chromatography Steps in the Platform Process, 189
  - 9.2.1 Capture Step: General Considerations, 189
  - 9.2.2 Intermediate/Polishing Steps, 191
- 9.3 Virus Inactivation, 193
- 9.4 UF/DF Platform Development, 194
  - 9.4.1 Use in Platform Processes, 194
  - 9.4.2 Challenges, 194
  - 9.4.3 Application Examples, 195
- 9.5 Platform Development: Virus Filtration and Bulk Fill, 195
  - 9.5.1 Virus Filtration in Platform Processes, 195
  - 9.5.2 Bulk Fill in Platform Processes, 196
- 9.6 Examples of Platform Processes, 196
  - 9.6.1 Example 1: Three-Column Protein A-Based Process, 196
  - 9.6.2 Example 2: Three-Column HCIC-Based Process, 197
  - 9.6.3 Example 3: Two- or One-Column Process without Protein A, 198
- 9.7 Developing a Viral Clearance Database Using a Platform Process, 199
- 9.8 Summary, 200
- 9.9 References, 201

## **10 Advances in Technology and Process Development for Industrial-Scale Monoclonal Antibody Purification** **203**

*Nuno Fontes and Robert van Reis*

- 10.1 Introduction, 203
- 10.2 Affinity Purification Platform, 204
  - 10.2.1 Overview, 204
  - 10.2.2 Standard Purification Sequence, 205
  - 10.2.3 Challenges and Opportunities, 205
- 10.3 Advances in CEX Purification of mAbs, 206
  - 10.3.1 Overview, 206
  - 10.3.2 High-Capacity CEX, 207
  - 10.3.3 An Exclusion Mechanism in Ion-Exchange Chromatography, 207
  - 10.3.4 Factors Affecting the Critical Conductivity, 210
  - 10.3.5 Advances in mAb CEX Process Development, 213

10.4	HPTFF, 215	
10.4.1	Overview, 215	
10.4.2	Advances in HPTFF, 217	
10.5	A New Nonaffinity Platform, 218	
10.6	References, 219	
<b>11</b>	<b>Continuous Chromatography for the Purification of Monoclonal Antibodies</b>	<b>223</b>
	<i>Thomas Müller-Späth and Massimo Morbidelli</i>	
11.1	Introduction, 223	
11.2	Product Variants and the Separation Problem, 224	
11.3	Definition of Performance Parameters, 225	
11.4	Gradient Chromatography for Biomolecules, 225	
11.5	Continuous Chromatography to Increase Productivity, 226	
11.5.1	The Concept of Continuous Chromatography, 226	
11.5.2	The Simulated Moving Bed (SMB) Process, 226	
11.5.3	Advantages and Disadvantages of Batch and SMB Chromatography, 227	
11.6	The MCSGP Process, 229	
11.6.1	MCSGP Process Design, 229	
11.6.2	MCSGP for the Capture of mAbs from Clarified Cell Culture Supernatants, 230	
11.6.3	MCSGP for the Separation of mAb Variants, 232	
11.7	Upgrades for Continuous Processes to Improve Stability, 233	
11.8	Impact of Increasing Fermentation Titrers, 233	
11.9	Outlook, 236	
11.10	Acknowledgments, 237	
11.11	References, 237	
<b>12</b>	<b>Process Economic Drivers in Industrial Monoclonal Antibody Manufacture</b>	<b>239</b>
	<i>Suzanne S. Farid</i>	
12.1	Introduction, 239	
12.2	Challenges When Striving for the Cost-Effective Manufacture of mAbs, 240	
12.2.1	Constraints, 240	
12.2.2	Uncertainties, 241	
12.3	Cost Definitions and Benchmark Values, 242	
12.3.1	Capital Investment, 242	
12.3.2	Cost of Goods (COG) per Gram, 243	
12.4	Economies of Scale, 246	
12.5	Overall Process Economic Drivers, 247	
12.5.1	Titer, 247	
12.5.2	Overall DSP Yield, 248	

- 12.5.3 Batch Duration, 250
- 12.5.4 Batch Success Rate, 250
- 12.5.5 Logistics, 251
- 12.6 DSP Drivers at High Titers, 251
  - 12.6.1 Material Reuse and Lifetime, 252
  - 12.6.2 Buffer/WFI Demands, 253
  - 12.6.3 Chromatography Capacity, 254
- 12.7 Process Economic Trade-Offs for DSP Bottlenecks, 254
  - 12.7.1 Chromatography Resin Dynamic Binding Capacity, 254
  - 12.7.2 Chromatography Flow Rates, 255
  - 12.7.3 Chromatography Resin Cycle Limits, 255
  - 12.7.4 Platform Processes, 255
  - 12.7.5 Alternatives to Chromatography, 256
- 12.8 Summary and Outlook, 256
- 12.9 References, 257

### **13 Design and Optimization of Manufacturing**

263

*Andrew Sinclair*

- 13.1 Introduction, 263
- 13.2 Process Design and Optimization, 265
- 13.3 Modeling Approaches, 267
  - 13.3.1 Cost Modeling for mAb Manufacture, 267
  - 13.3.2 Process Simulation for mAb Manufacture, 274
- 13.4 Cost Models in Practice, 279
  - 13.4.1 Manufacturing Strategies—Disposables vs. Continuous, 280
  - 13.4.2 Manufacturing Technologies—Single-Use Systems, 281
- 13.5 Simulation in Practice, 286
  - 13.5.1 Managing Multiproduct Manufacture, 286
  - 13.5.2 Resource Management, 288
- 13.6 Acknowledgments, 290
- 13.7 References, 290

### **14 Alternatives to Packed-Bed Chromatography for Antibody Extraction and Purification**

293

*Jörg Thömmes and Uwe Gottschalk*

- 14.1 Introduction, 293
- 14.2 Increasing the Selectivity of Harvest Procedures: Flocculation of Particulate and Nonparticulate Impurities, 294
- 14.3 Solutions for Antibody Extraction, Concentration, and Purification, 295



14.3.1	Extraction and Concentration by Precipitation, 295	
14.3.2	Extraction and Concentration by Liquid-Phase Partitioning, 297	
14.3.3	Concentration by Evaporation, 298	
14.4	Nonchromatographic Solutions for Antibody Purification and Formulation, 298	
14.4.1	Crystallization, 298	
14.4.2	Controlled Freeze–Thaw, 300	
14.4.3	Lyophilization, 301	
14.5	Membrane Adsorbers, 302	
14.6	Conclusions, 304	
14.7	Acknowledgments, 305	
14.8	References, 305	
<b>15</b>	<b>Process-Scale Precipitation of Impurities in Mammalian Cell Culture Broth</b>	<b>309</b>
	<i>Judy Glynn</i>	
15.1	Introduction, 309	
15.2	Precipitation of DNA and Protein—Other Applications, 311	
15.3	A Comprehensive Evaluation of Potential Precipitants for Impurity Removal, 312	
15.3.1	Protocol, 312	
15.3.2	Ammonium Sulfate Precipitation, 314	
15.3.3	Polymer Precipitation, 315	
15.3.4	Precipitation with Ionic Liquids, 315	
15.3.5	Precipitation with Cationic Detergents, 315	
15.3.6	Ethacridine Precipitation, 316	
15.3.7	Caprylic Acid Precipitation, 317	
15.4	Industrial-Scale Precipitation, 319	
15.5	Cost of Goods Comparison, 320	
15.6	Summary, 321	
15.7	Acknowledgments, 321	
15.8	References, 322	
<b>16</b>	<b>Charged Ultrafiltration and Microfiltration Membranes in Antibody Purification</b>	<b>325</b>
	<i>Mark R. Etzel</i>	
16.1	Introduction, 325	
16.2	Charged Ultrafiltration Membranes, 326	
16.3	Concentration Polarization and Permeate Flux, 327	
16.4	Stagnant Film Model (SFM), 328	
16.5	Osmotic Pressure Model, 328	

16.6	Mass Transfer Coefficient, 329	
16.7	Sieving Coefficient, 329	
16.8	Diffusion–Convection Model, 330	
16.9	Scale-up Strategies and the Constant Wall Concentration ( $C_w$ ) Approach, 331	
16.10	Protein Fractionation Using Charged Ultrafiltration Membranes, 333	
16.11	Case Study, 333	
	16.11.1 Methods, 334	
	16.11.2 Results, 334	
	16.11.3 Discussion, 337	
16.12	Membrane Cascades, 337	
16.13	Charged Microfiltration Membranes, 339	
16.14	Virus Clearance, 339	
16.15	Salt Tolerance, 341	
16.16	Conclusions, 343	
16.17	Acknowledgments, 344	
16.18	References, 345	
<b>17</b>	<b>Downstream Processing of Monoclonal Antibody Fragments</b>	<b>349</b>
	<i>Mariangela Spitali</i>	
17.1	Introduction, 349	
17.2	Production of Antibody Fragments for Therapeutic Use, 351	
17.3	Downstream Processing, 351	
	17.3.1 Primary Recovery, 352	
	17.3.2 Capture, 356	
	17.3.3 Expanded-Bed Chromatography, 361	
	17.3.4 Further Purification and Polishing, 362	
17.4	Improving the Pharmacological Characteristics of Antibody Fragments, 365	
17.5	Conclusions, 367	
17.6	Acknowledgments, 368	
17.7	References, 369	
<b>18</b>	<b>Purification of Antibodies Other Than IgG: The Case of IgM and IgA</b>	<b>373</b>
	<i>Charlotte Cabanne and Xavier Santarelli</i>	
18.1	Introduction, 373	
18.2	Purification of Immunoglobulin M (IgM), 374	
	18.2.1 IgM Structure and Properties, 374	
	18.2.2 IgM Purification Technologies, 374	
	18.2.3 Affinity and Pseudoaffinity Matrices, 376	

- 18.3 Purification of IgA, 378
  - 18.3.1 IgA Structure and Properties, 378
  - 18.3.2 Affinity and Pseudoaffinity Matrices, 378
- 18.4 Conclusion, 380
- 18.5 Acknowledgments, 380
- 18.6 References, 380
  
- 19 Purification of Antibodies From Transgenic Plants 387**  
*Zivko L. Nikolov, Jeffrey T. Regan, Lynn F. Dickey, and Susan L. Woodard*
  - 19.1 Introduction, 387
  - 19.2 Antibody Production in Transgenic Plants, 388
    - 19.2.1 Subcellular Localization and Glycosylation, 388
    - 19.2.2 Other Factors Affecting mAb Accumulation, 390
  - 19.3 Downstream Processing of Antibodies Produced in Transgenic Plants, 391
    - 19.3.1 Tissue Disintegration, 393
    - 19.3.2 Solid–Liquid Separation, 394
    - 19.3.3 Clarification and Pretreatment of Crude Extracts, 395
  - 19.4 Purification of Plant-Derived mAbs Using Protein A, 396
  - 19.5 Purification of Plant-Derived mAbs Using Nonprotein A Media, 397
  - 19.6 Polishing Steps, 398
  - 19.7 Conclusions, 399
  - 19.8 Acknowledgments, 401
  - 19.9 References, 401
  
- 20 Antibody Purification: Drivers of Change 407**  
*Narahari Pujar, Duncan Low, and Rhona O’Leary*
  - 20.1 Introduction, 407
  - 20.2 The Changing Regulatory Environment—Pharmaceutical Manufacturing for the Twenty-First Century, 410
    - 20.2.1 Using Design Space to Enable Change, 412
    - 20.2.2 High-Throughput and Microscale Approaches to Process Development and Characterization, 415
  - 20.3 Technology Drivers—Advances and Innovations, 416
    - 20.3.1 PAT, 416
    - 20.3.2 Process Control Technology, 417
  - 20.4 Economic Drivers, 418
    - 20.4.1 Cost of Goods (COG), 418
    - 20.4.2 Single-Use Disposable Components, 418
    - 20.4.3 Globalization, 419
    - 20.4.4 Follow-on Biologics (FOBs) or Biosimilars, 420

## CONTENTS

**xv**

- 20.5 Conclusions, 421
- 20.6 Acknowledgments, 422
- 20.7 References, 422

## **Index**

**427**